Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

November 2019

Cumulative for August, September, October and November 2019

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 NOVEMBER 2019

- Adrenaline (DBL Adrenaline) inj 1 in 1,000, 1 ml ampoule – amended brand name
- Amisulpride (Sulprix) tab 400 mg – price increase and addition of HSS
- Amoxicillin (Alphamox) cap 250 mg and 500 mg – new listing and addition of HSS
- Amoxicillin (Apo-Amoxi) cap 250 mg and 500 mg – to be delisted 1 April 2020
- Benzocaine with tetracaine hydrochloride (e.g. ZAP Topical Anaesthetic Gel) gel 18% with tetracaine hydrochloride 2% – new listing
- Benzylpenicillin sodium [penicillin G] (Pan-Penicillin G Sodium) inj 600 mg (1 million units) vial – new listing
- Bupivacaine hydrochloride with fentanyl (Biomed) inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag – new listing and addition of HSS
- Buprenorphine with naloxone (Buprenorphine Naloxone BNM) tab 2 mg with naloxone 0.5 mg and 8 mg with naloxone 2 mg – new listing and addition of HSS
- Buprenorphine with naloxone (Suboxone) tab 2 mg with naloxone 0.5 mg and 8 mg with naloxone 2 mg – to be delisted 1 April 2020
- Clarithromycin tab 250 mg and 500 mg (Apo-Clarithromycin), grans for oral liq 50 mg per ml (Klacid) and inj 500 mg vial (Martindale) – amended restriction criteria
- Compound electrolytes (Electral) powder for oral soln – new listing and addition of HSS
- Compound electrolytes (Enerlyte) powder for oral soln – to be delisted 1 April 2020
- Disulfiram (Antabuse) tab 200 mg – price increase
- Enteral feed 2kcal/ml (Nutrison Concentrated) liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle – new Pharmacode listing
- Eptacog alfa [recombinant factor VIIA] (NovoSeven RT) inj 1 mg, 2 mg, 5 mg and 8 mg syringe – amended restriction criteria
- Extensively hydrolysed formula powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can (Allerpro 1) and powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can (Allerpro 2) – new listing
- Factor eight inhibitor bypassing fraction (FEIBA NF) inj 500 u, 1,000 U and 2,500 U – amended restriction criteria
- Famotidine tab 20 mg, 40 mg and inj 10 mg per ml, 4 ml vial – new listing

Summary of decisions – effective 1 November 2019 (continued)

- Fluoxetine hydrochloride (Fluox) tab dispersible 20 mg, scored and cap 20 mg – new listing and addition of HSS
- Fluoxetine hydrochloride (Arrow-Fluoxetine) tab dispersible 20 mg, scored and cap 20 mg – to be delisted 1 April 2020
- Iron polymaltose (Ferrum H) inj 50 mg per ml, 2 ml ampoule – to be delisted 1 February 2020
- Loratadine (Lorafix) tab 10 mg – price increase and addition of HSS
- Levomepromazine hydrochloride (Nozinan) inj 25 mg per ml, 1 ml ampoule – new listing and addition of HSS
- Levomepromazine hydrochloride (Wockhardt) inj 25 mg per ml, 1 ml ampoule – to be delisted 1 April 2020
- Levonorgestrel (Jaydess) intra-uterine device 13.5 mg – new listing and addition of HSS
- Levonorgestrel (Mirena) intra-uterine device 52 mg – addition of HSS, amended presentation description and restriction criteria removed
- Metaraminol inj 0.5 mg per ml, 5 ml and 10 ml syringe – new listing
- Moroctocog alfa [recombinant factor VIII] (Xyntha) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu prefilled syringe – price increase and amended restriction criteria
- Moxifloxacin (Moxifloxacin Kabi) inj 1.6 mg per ml, 250 ml bottle – new listing and addition of HSS
- Moxifloxacin (Avelox IV 400) inj 1.6 mg per ml, 250 ml bottle – to be delisted 1 April 2020
- Octocog alfa [recombinant factor VIII] (Advate) inj 250 iu, 500 iu, 1,000 iu, 1,500 iu. 2,000 iu and 3,000 iu vial – amended restriction criteria
- Octocog alfa [recombinant factor VIII] (Kogenate FS) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu vial – amended restriction criteria
- Ondansetron (Onrex) tab 4 mg and 8 mg – new listing and addition of HSS
- Ondansetron (Apo-Ondansetron) tab 4 mg and 8 mg – to be delisted 1 April 2020
- Paraffin (healthE) white soft, 450 g – new listing and addition of HSS
- Prilocaine hydrochloride inj 2%, 5 ml ampoule – new listing
- Ranitidine tab 150 mg and 300 mg (Ranitidine Relief), oral liq 150 mg per 10 ml (Peptisoothe) and inj 25 mg per ml, 2 ml ampoule (Zantac) – restriction added
- Tocilizumab (Actemra) inj 20 mg per ml, 4 ml, 10 ml and 20 ml vial – amended restriction criteria

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 November 2019

ALIMENTARY TRACT AND METABOLISM

7 FAMOTIDINE (new listing)
Tab 20 mg
Tab 40 mg
Inj 10 mg per ml, 4 ml vial

7 RANITIDINE – restriction added

➔ Tab 150 mg – **1% DV Oct-17 to 2020**	12.91	500	**Ranitidine Relief**
➔ Tab 300 mg – **1% DV Oct-17 to 2020**	18.21	500	**Ranitidine Relief**
➔ Oral liq 150 mg per 10 ml – **1% DV Oct-17 to 2020**	5.14	300 ml	**Peptisoothe**
➔ Inj 25 mg per ml, 2 ml ampoule	8.75	5	Zantac

Restricted
Initiation
Either:
1 For continuation use; or
2 Routine prevention of allergic reactions.

18 IRON POLYMALTOSE (delisting)

Inj 50 mg per ml, 2 ml ampoule	15.22	5	Ferrum H

Note – Ferrum H inj 50 mg per ml, 2 ml ampoule to be delisted from 1 February 2020.

BLOOD AND BLOOD FORMING ORGANS

27 EPTACOG ALFA [RECOMBINANT FACTOR VIIA] (amended restriction criteria)

➔ Inj 1 mg syringe	1,178.30	1	NovoSeven RT
➔ Inj 2 mg syringe	2,356.60	1	NovoSeven RT
➔ Inj 5 mg syringe	5,891.50	1	NovoSeven RT
➔ Inj 8 mg syringe	9,426.40	1	NovoSeven RT

Restricted
Initiation
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. **Rare Clinical Circumstances Brand of bypassing agent for >14 days predicted use. Access to funded treatment for >14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.**

27 FACTOR EIGHT INHIBITOR BYPASSING FRACTION (amended restriction criteria)

➔ Inj 500 U	1,315.00	1	FEIBA NF
➔ Inj 1,000 U	2,630.00	1	FEIBA NF
➔ Inj 2,500 U	6,575.00	1	FEIBA NF

Restricted
Initiation
For patients with haemophilia. **Preferred Brand of bypassing agent for >14 days predicted use.** Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 November 2019 (continued)

27 MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] (↑ price and amended restriction criteria)

➔ Inj 250 iu prefilled syringe	287.50	1	Xyntha
➔ Inj 500 iu prefilled syringe	575.00	1	Xyntha
➔ Inj 1,000 iu prefilled syringe	1,150.00	1	Xyntha
➔ Inj 2,000 iu prefilled syringe	2,300.00	1	Xyntha
➔ Inj 3,000 iu prefilled syringe	3,450.00	1	Xyntha

Restricted
Initiation
For patients with haemophilia. **Rare Clinical Circumstances Brand of short half-life recombinant factor VIII.** Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group**, subject to criteria**.

28 OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) (amended restriction criteria)

➔ Inj 250 iu vial	210.00	1	Advate
➔ Inj 500 iu vial	420.00	1	Advate
➔ Inj 1,000 iu vial	840.00	1	Advate
➔ Inj 1,500 iu vial	1,260.00	1	Advate
➔ Inj 2,000 iu vial	1,680.00	1	Advate
➔ Inj 3,000 iu vial	2,520.00	1	Advate

Restricted
Initiation
For patients with haemophilia. **Preferred Brand of short half-life recombinant factor VIII.** Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

28 OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) (amended restriction criteria)

➔ Inj 250 iu vial	237.50	1	Kogenate FS
➔ Inj 500 iu vial	475.00	1	Kogenate FS
➔ Inj 1,000 iu vial	950.00	1	Kogenate FS
➔ Inj 2,000 iu vial	1,900.00	1	Kogenate FS
➔ Inj 3,000 iu vial	2,850.00	1	Kogenate FS

Restricted
Initiation
For patients with haemophilia. **Rare Clinical Circumstances Brand of short half-life recombinant factor VIII.** Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group**, subject to criteria**.

35 COMPOUND ELECTROLYTES (brand change)

Powder for oral soln – **1% DV Apr-20 to 2022**	9.77	50	**Electral**

Note – Enerlyte powder for oral soln to be delisted from 1 April 2020.

CARDIOVASCULAR SYSTEM

46 ADRENALINE (amended brand name)

Inj 1 in 1,000, 1 ml ampoule	5.25	5	~~Hospira~~ **DBL Adrenaline**

47 METARAMINOL (new listing)

Inj 0.5 mg per ml, 5 ml syringe
Inj 0.5 mg per ml, 10 ml syringe

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 November 2019 (continued)

DERMATOLOGICALS

53 PARAFFIN (new listing)
White soft – **1% DV Apr-20 to 2022** ..... 4.99 450 g **healthE**

GENITO-URINARY SYSTEM

58 LEVONORGESTREL (new listing)
Intra-uterine device 13.5 mg
– 1% DV Nov-19 to 31 Oct 2022 ..... 215.60 1 **Jaydess**

58 LEVONORGESTREL (addition of HSS, amended presentation description and restriction criteria removed)
Intra-uterine ~~system, 20 mcg per day~~ **device 52 mg**
– 1% DV Nov-19 to 31 Oct 2022 ..... 269.50 1 **Mirena**

~~Restricted~~
~~Initiation – heavy menstrual bleeding~~
~~Obstetrician or gynaecologist~~
~~All of the following:~~
~~1. The patient has a clinical diagnosis of heavy menstrual bleeding; and~~
~~2. The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and~~
~~3. Any of the following:~~
~~3.1. Serum ferritin level < 16 mcg/l (within the last 12 months); or~~
~~3.2. Haemoglobin level < 120 g/l; or~~
~~3.3. The patient has had a uterine ultrasound and either a hysteroscopy or endometrial biopsy.~~

~~Continuation – heavy menstrual bleeding~~
~~Obstetrician or gynaecologist~~
~~Either:~~
~~1. Patient demonstrated clinical improvement of heavy menstrual bleeding; or~~
~~2. Previous insertion was removed or expelled within 3 months of insertion.~~

~~Initiation – endometriosis~~
~~Obstetrician or gynaecologist~~
~~The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy.~~

~~Continuation – endometriosis~~
~~Obstetrician or gynaecologist~~
~~Either:~~
~~1. Patient demonstrated satisfactory management of endometriosis; or~~
~~2. Previous insertion was removed or expelled within 3 months of insertion.~~
~~Note: endometriosis is an unregistered indication.~~

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 November 2019 (continued)

INFECTIONS

75 CLARITHROMYCIN (amended restriction criteria – affected criteria shown only)

➔ Tab 250 mg – **1% DV Sep-17 to 2020**	3.98	14	**Apo-Clarithromycin**
➔ Tab 500 mg – **1% DV Sep-17 to 2020**	10.40	14	**Apo-Clarithromycin**
➔ Grans for oral liq 50 mg per ml	23.12	50 ml	Klacid
➔ Inj 500 mg vial – **1% DV Dec-17 to 31 Aug 2020**	12.04	1	**Martindale**

Restricted
Initiation – Tab 250 mg and oral liquid
~~Either~~ **Any of the following:**
1 Atypical mycobacterial infection; or
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; **or**
3. Helicobacter pylori eradication; or
4. Prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated.

76 AMOXICILLIN (brand change)

Cap 250 mg – **1% DV Apr-20 to 2022**	22.50	500	**Alphamox**
Cap 500 mg – **1% DV Apr-20 to 2022**	36.98	500	**Alphamox**

Note – Apo-Amoxi cap 250 mg and 500 mg to be delisted from 1 April 2020.

76 BENZYLPENICILLIN SODIUM [PENICILLIN G]

Inj 600 mg (1 million units) vial	25.88	25	Pan-Penicillin G Sodium

77 MOXIFLOXACIN (brand change)

➔ Inj 1.6 mg per ml, 250 ml bottle – **1% DV Apr-20 to 2022**	39.00	1	**Moxifloxacin Kabi**

Note – Avelox IV 400 inj 1.6 mg per ml, 250 ml bottle to be delisted from 1 April 2020.

NERVOUS SYSTEM

105 BENZOCAINE WITH TETRACAINE HYDROCHLORIDE (new listing)

Gel 18% with tetracaine hydrochloride 2%			*e.g. ZAP Topical Anaesthetic Gel*

105 BUPIVACAINE HYDROCHLORIDE WITH FENTANYL (new listing)

Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag – **1% DV Apr-20 to 2022**	305.00	10	**Biomed**

106 PRILOCAINE HYDROCHLORIDE (new listing)
Inj 2%, 5 ml ampoule

111 FLUOXETINE HYDROCHLORIDE (brand change)

Tab dispersible 20 mg, scored – **1% DV Apr-20 to 2022**	1.98	30	**Fluox**
Cap 20 mg – **1% DV Apr-20 to 2022**	2.91	84	**Fluox**

Note – Arrow-Fluoxetine tab dispersible 20 mg, scored and cap 20 mg to be delisted from 1 April 2020.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 November 2019 (continued)

116 ONDANSETRON (brand change)

Tab 4 mg – **1% DV Apr-20 to 2022**	2.68	50	**Onrex**
Tab 8 mg – **1% DV Apr-20 to 2022**	4.57	50	**Onrex**

Note – Apo-Ondansetron tab 4 mg and 8 mg to be delisted from 1 April 2020.

117 AMISULPRIDE (↑ price and addition of HSS)

Tab 400 mg – **1% DV Feb-20 to 2022**	29.78	60	**Sulprix**

118 LEVOMEPROMAZINE HYDROCHLORIDE (brand change)

Inj 25 mg per ml, 1 ml ampoule – **1% DV Apr-20 to 2022**	33.50	10	**Nozinan**

Note – Wockhardt inj 25 mg per ml, 1 ml ampule to be delisted from 1 April 2020.

125 BUPRENORPHINE WITH NALOXONE (brand change)

➔ Tab 2 mg with naloxone 0.5 mg – **1% DV Apr-20 to 2022**	18.37	28	**Buprenorphine Naloxone BNM**
➔ Tab 8 mg with naloxone 2 mg – **1% DV Apr-20 to 2022**	53.12	28	**Buprenorphine Naloxone BNM**

Note – Suboxone tab 2 mg with naloxone 0.5 mg and tab 8 mg with naloxone 2 mg to be delisted from 1 April 2020.

126 DISULFIRAM (↑ price)

Tab 200 mg	153.00	100	Antabuse

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

179 TOCILIZUMAB (amended restriction – affected criteria shown only)

➔ Inj 20 mg per ml, 4 ml vial	220.00	1	Actemra
➔ Inj 20 mg per ml, 10 ml vial	550.00	1	Actemra
➔ Inj 20 mg per ml, 20 ml vial	1,100.00	1	Actemra

Restricted
Initiation – cytokine release syndrome
Treatment limited to 3 doses.
Either:
1 All of the following:
  1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
  1.2 The patient has developed grade 3 or 4 cytokine release syndrome (CRS) associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
  1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses **(if less than 30kg, maximum of 12 mg/kg)**; or
2 All of the following:
  2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
  2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
  2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 November 2019 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

189 LORATADINE (↑ price and addition of HSS)
Tab 10 mg – **1% DV Feb-20 to 2022** ..... 1.69 100 **Lorafix**

SPECIAL FOODS

221 ENTERAL FEED 2 KCAL/ML (Pharmacode change)
➔ Liquid 7.5 g protein, 20 g carbohydrate and
10 g fat per 100 ml, bottle ..... 5.50 500 ml Nutrison Concentrated
Note – this is a new Pharmacode listing, 2572966. Pharmacode 2057808 to be delisted from 1 May 2020.

223 EXTENSIVELY HYDROLYSED FORMULA (new listing)
➔ Powder 1.6 g protein, 7.5 g carbohydrate and
3.1 g fat per 100 ml, 900 g can ..... 30.42 900 g Allerpro 1
➔ Powder 1.6 g protein, 7.8 g carbohydrate and
3.2 g fat per 100 ml, 900 g can ..... 30.42 900 g Allerpro 2

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 October 2019

ALIMENTARY TRACT AND METABOLISM

5 CALCIUM CARBONATE (amended restriction criteria)
➔ Oral liq 250 mg per ml (100 mg elemental per ml) ..... 39.00 500 ml Roxane

Restricted
Initiation
Only ~~for use in children under 12 years of age for use as a phosphate binding agent~~ **when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate**.

BLOOD AND BLOOD FORMING ORGANS

32 UROKINASE (new listing)
Inj 5,000 iu vial

CARDIOVASCULAR SYSTEM

42 NICARDIPINE HYDROCHLORIDE (amended restriction criteria)
➔ Inj 2.5 mg per ml, 10 ml vial

Restricted
Initiation
Anaesthetist, intensivist, **cardiologist** or paediatric cardiologist
~~Both:~~
~~1 Patient is a Paediatric Patient; and~~
~~2~~ Any of the following:
~~2.~~1 Patient has hypertension requiring urgent treatment with an intravenous agent; or
~~2.~~2 Patient has excessive ventricular afterload; or
~~2.~~3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

42 VERAPAMIL HYDROCHLORIDE (brand change)
Tab long-acting 120 mg ..... 36.02 100 Isoptin SR
Note – Verpamil SR tab long-acting 120 mg to be delisted from 1 May 2020.

50 ILOPROST (↓ price and addition of HSS)
➔ Nebuliser soln 10 mcg per ml, 2 ml
– **1% DV Jan-20 to 2022** ..... 740.10 30 **Ventavis**

46 GLYCERYL TRINITRATE (delisting)
Oral spray, 400 mcg per dose ..... 4.45 200 dose Glytrin
Note – Glytrin oral spray, 400 mcg per dose to be delisted from 1 May 2020.

DERMATOLOGICALS

53 CETOMACROGOL WITH GLYCEROL (brand change)
Crm 90% with glycerol 10% – **1% DV Mar-20 to 2022** ..... 2.35 500 ml **Boucher**
3.10 1,000 ml **Boucher**
Note – Pharmacy Health Sorbolene with glycerine crm 90% with glycerol 10%, 500 ml and 1,000 ml pack to be delisted from 1 March 2020.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 October 2019 (continued)

56 SUNSCREEN, PROPRIETARY (delisting)
Crm
Note – sunscreen, proprietary crm to be delisted from 1 March 2020.

56 SUNSCREEN, PROPRIETARY (addition of HSS)

Lotn – **1% DV Mar-20 to 2022**	5.10	200 g	**Marine Blue Lotion SPF 50+**

Note - Marine Blue Lotion SPF 50+ lotn, 100 g pack to be delisted from 1 March 2020.

GENITO-URINARY SYSTEM

57 CLOTRIMAZOLE (↑ price and addition of HSS)

Vaginal crm 1% with applicator – **1% DV Jan-20 to 2022**	2.50	35 g	**Clomazol**
Vaginal crm 2% with applicator – **1% DV Jan-20 to 2022**	3.00	20 g	**Clomazol**

57 ETHINYLOESTRADIOL WITH NORETHISTERONE (new listing)

Tab 35 mcg with norethisterone 1 mg and 7 inert tab – **1% DV Mar-20 to 2022**	6.95	84	**Brevinor 1/28**

60 TAMSULOSIN HYDROCHLORIDE (↑ price and addition of HSS)

➔ Cap 400 mcg – **1% DV Jan-20 to 2022**	17.73	100	**Tamsulosin-Rex**

61 TOLTERODINE TARTRATE (delisting)

➔ Tab 1 mg	14.56	56	Arrow-Tolterodine

Note – Arrow-Tolteroine tab 1 mg to be delisted from 1 March 2020.

HORMONE PREPARATIONS

65 NORETHISTERONE (addition of HSS)

Tab 5 mg – **1% DV Dec-19 to 2021**	18.29	100	**Primolut N**

INFECTIONS

76 BENZYLPENICILLIN SODIUM [PENICILLIN G] (new listing)

Inj 600 mg (1 million units) vial	103.50	100	Sandoz

Note – this is a new Pharmacode listing, 2574276.

76 PHENOXYMETHYLPENICILLIN [PENICILLIN V] (↑ price and addition of HSS)

Grans for oral liq 125 mg per 5 ml – **1% DV Jan-20 to 2022**	2.99	100 ml	**AFT**
Grans for oral liq 250 mg per 5 ml – **1% DV Jan-20 to 2022**	3.99	100 ml	**AFT**

78 CLINDAMYCIN (brand change)

➔ Cap 150 mg – **1% DV Apr-20 to 2022**	4.61	24	**Dalacin C**

Note – Clindamycin ABM cap 150 mg to be delisted from 1 April 2020.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 October 2019 (continued)

90 EMTRICITABINE WITH TENOFOVIR DISOPROXIL (amended restriction criteria - affected criteria shown only)
➔ Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)
– **1% DV Jun-19 to 2022**.....61.15 30 **Teva**

Initiation – Pre-exposure prophylaxis
Re-assessment required after 3 months
All of the following ~~Both~~:
1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
2 Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 3 months and is not contraindicated for treatment; and
4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5 ~~1~~ Patient has tested HIV negative **and is not at risk of HIV seroconversion**; and
6 ~~2~~ Either:
6.1 ~~2.1~~ All of the following:
6.1.1 ~~2.1.1~~ Patient is male or transgender; and
6.1.2 ~~2.1.2~~ Patient has sex with men; and
6.1.3 ~~2.1.3~~ Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
6.1.4 ~~2.1.4~~ Any of the following:
6.1.4.1 ~~2.1.4.1~~ Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
6.1.4.2 ~~2.1.4.2~~ A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
6.1.4.3 ~~2.1.4.3~~ Patient has used methamphetamine in the last three months; or
6.2 ~~2.2~~ All of the following:
6.2.1 ~~2.2.1~~ Patient has a regular partner who has HIV infection; and
6.2.2 ~~2.2.2~~ Partner is either not on treatment or has a detectable viral load; and
6.2.3 ~~2.2.3~~ Condoms have not been consistently used.

Continuation – Pre-exposure prophylaxis
Re-assessment required after 3 months
All of the following:
1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis **(refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials)**; and
2 Patient has undergone testing for HIV, syphilis, **Hep B if not immune** and a full STI screen in the previous two weeks; and
3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months **and is not contraindicated for treatment**; and
4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5 Patient has tested HIV negative **and is not at risk of HIV seroconversion**; and
6 Either:
6.1 All of the following:
6.1.1 Patient is male or transgender; and
6.1.2 Patient has sex with men; and
6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and

continued...

Changes to Section H Part II – effective 1 October 2019 (continued)

continued...

6.1.4 Any of the following:
- 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
- 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
- 6.1.4.3 Patient has used methamphetamine in the last three months; or

6.2 All of the following:
- 6.2.1 Patient has a regular partner who has HIV infection; and
- 6.2.2 Partner is either not on treatment or has a detectable viral load; and
- 6.2.3 Condoms have not been consistently used.

MUSCULOSKELETAL SYSTEM

100	PANCURONIUM BROMIDE (delisting)			
	Inj 2 mg per ml, 2 ml ampoule	260.00	50	AstraZeneca
	Note – AstraZeneca inj 2 mg per ml, 2 ml ampoule to be delisted from 1 January 2020.			

NERVOUS SYSTEM

104	ROPINIROLE HYDROCHLORIDE (brand change)			
	Tab 0.25 mg – **1% DV Mar-20 to 2022**	2.85	84	**Ropin**
	Tab 1 mg – **1% DV Mar-20 to 2022**	3.95	84	**Ropin**
	Tab 2 mg – **1% DV Mar-20 to 2022**	5.48	84	**Ropin**
	Tab 5 mg – **1% DV Mar-20 to 2022**	12.50	84	**Ropin**
	Note – Apo-Ropinirole tab 0.25 mg, 1 mg, 2 mg and 5 mg to be delisted from 1 March 2020.			
109	MORPHINE SULPHATE (↑ price and addition of HSS)			
	Cap long-acting 10 mg – **1% DV Jan-20 to 2022**	2.05	10	**m-Eslon**
	Cap long-acting 30 mg – **1% DV Jan-20 to 2022**	3.00	10	**m-Eslon**
	Cap long-acting 60 mg – **1% DV Jan-20 to 2022**	6.12	10	**m-Eslon**
	Cap long-acting 100 mg – **1% DV Jan-20 to 2022**	7.13	10	**m-Eslon**
111	PAROXETINE (brand change)			
	Tab 20 mg – **1% DV Mar-20 to 2022**	3.61	90	**Loxamine**
	Note – Apo-Paroxetine tab 20 mg to be delisted from 1 March 2020.			
111	SERTRALINE (brand change)			
	Tab 50 mg – **1% DV Mar-20 to 2022**	0.92	30	**Setrona**
	Tab 100 mg – **1% DV Mar-20 to 2022**	1.61	30	**Setrona**
	Note – Arrow-Sertraline tab 50 mg and 100 mg to be delisted from 1 March 2020.			
116	METOCLOPRAMIDE HYDROCHLORIDE (↓ price and addition of HSS)			
	Inj 5 mg per ml, 2 ml ampoule – **1% DV Jan-20 to 2022**	9.50	10	**Pfizer**

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 October 2019 (continued)

126 VARENICLINE (amended restriction criteria)

➔ Tab 0.5 mg × 11 and 1 mg × 42 – **1% DV Mar-19 to 2021**	25.64	53	**Varenicline Pfizer**
➔ Tab 1 mg – **1% DV Mar-19 to 2021**	27.10	56	**Varenicline Pfizer**

Restricted
Initiation
All of the following:

1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
3 Either:
   3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
   3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
4 ~~The patient has not used funded varenicline in the last 12 months~~ **The patient has not had a Special Authority for varenicline approved in the last 6 months**; and
5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
6 The patient is not pregnant; and
7 The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

134 TEMOZOLOMIDE (brand change)

➔ Cap 20 mg – **1% DV May-20 to 2022**	16.38	5	**Temaccord**
➔ Cap 100 mg – **1% DV May-20 to 2022**	35.98	5	**Temaccord**
➔ Cap 140 mg – **1% DV May-20 to 2022**	50.12	5	**Temaccord**
➔ Cap 250 mg – **1% DV May-20 to 2022**	86.34	5	**Temaccord**

Note – Orion Temozolomide cap 20 mg, 100 mg and 250 mg to be delisted from 1 May 2020.

142 CALCIUM FOLINATE (↑ price and addition of HSS)

Inj 10 mg per ml, 5 ml vial – **1% DV Jan-20 to 2022**	7.28	1	**Calcium Folinate Sandoz**
Inj 10 mg per ml, 100 ml vial – **1% DV Mar-20 to 2022**	72.00	1	**Calcium Folinate Sandoz**

142 CALCIUM FOLINATE (delisting)

Inj 10 mg per ml, 100 ml vial	67.51	1	Calcium Folinate Ebewe

Note – Calcium Folinate Ebewe inj 10 mg per ml, 100 ml vial to be delisted from 1 March 2020.

Changes to Section H Part II – effective 1 October 2019 (continued)

151 ADALIMUMAB (amended restriction – new criteria shown only)

➔ Inj 20 mg per 0.4 ml syringe ..... 1,599.96 2 Humira
➔ Inj 40 mg per 0.8 ml pen ..... 1,599.96 2 HumiraPen
➔ Inj 40 mg per 0.8 ml syringe ..... 1,599.96 2 Humira

Restricted
Initiation – hidradenitis suppurativa
Dermatologist
Re-assessment required after 4 months.
All of the following:
1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
3 The patient has 3 or more active lesions (e.g. inflammatory nodules, abscesses, draining fistulae); and
4 The patient has a Dermatology Quality of Life Index of 10 or more and the assessment is no more than 1 month old at time of application; and
5 Following the initial loading doses, adalimumab is to be administered at doses no greater than 40mg every 7 days.

Continuation – hidradenitis suppurativa
Dermatologist
Re-assessment required after 6 months.
All of the following:
1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

VARIOUS

205 POVIDONE-IODINE (new listing)
Soln 10% – **1% DV Dec-19 to 2021** ..... 3.83 15 ml **Riodine**

205 POVIDONE-IODINE (↓ price and addition of HSS)
Soln 10% – **1% DV Dec-19 to 2021** ..... 5.40 500 ml **Riodine**
Note – Betadine soln 10% to be delisted from 1 December 2019.

SPECIAL FOODS

222 AMINO ACID FORMULA (new listing)
➔ Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can ..... 53.00 400 g Neocate Junior Vanilla

222 AMINO ACID FORMULA (delisting)
➔ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can ..... 53.00 400 g Neocate Junior Vanilla
Note – Neocate Junior Vanilla Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can to be delisted 1 April 2020.

222 HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML (amended presentation description)
➔ Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml ~~bag~~ **bottle** *e.g. Nutrison Protein Plus*

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2019

ALIMENTARY TRACT AND METABOLISM

6 SULFASALAZINE (↑ price and addition of HSS)
Tab EC 500 mg – **1% DV Dec-19 to 2022** ..... 15.53 100 **Salazopyrin EN**

17 CALCIUM CARBONATE (new listing)
Tab eff 1.75 g (1 g elemental)

18 ZINC SULPHATE (addition of HSS)
Cap 137.4 mg (50 mg elemental) – **1% DV Dec-19 to 2022** .... 11.00 100 **Zincaps**

BLOOD AND BLOOD FORMING ORGANS

31 ASPIRIN (↑ price)
Tab 100 mg ..... 1.95 90 Ethics Aspirin EC

31 LYSINE ACETYLSALICYLATE **[LYSINE ASPIRIN]** (amended chemical name)
➔ Inj 500 mg *e.g. Aspegic*

35 WATER (new listing)
Inj 20 ml ampoule..... 5.00 20 Fresenius Kabi

CARDIOVASCULAR SYSTEM

37 CILAZAPRIL (brand change)
Tab 2.5 mg – **1% DV Feb-20 to 2022**..... 4.80 90 **Zapril**
Tab 5 mg – **1% DV Feb-20 to 2022**..... 8.35 90 **Zapril**
Note – Apo-Cilazapril tab 2.5 mg and 5 mg to be delisted from 1 February 2020.

39 ADENOSINE (new listing)
Inj 3 mg per ml, 2 ml vial – **1% DV Feb-20 to 2022** ..... 62.73 6 **Adenocor**

39 AMIODARONE HYDROCHLORIDE (brand change)
Inj 50 mg per ml, 3 ml ampoule – **1% DV Feb-20 to 2022** ..... 16.37 10 **Max Health**
Note – Cordarone-X and Lodi inj 50 mg per ml, 3 ml ampoule to be delisted from 1 February 2020.

39 FLECAINIDE ACETATE (brand change)
Tab 50 mg – **1% DV Feb-20 to 2022**..... 19.95 60 **Flecainide BNM**
Note – Tambocor tab 50 mg to be delisted from 1 February 2020.

44 CHLORTALIDONE [CHLORTHALIDONE] (↓ price and addition of HSS)
Tab 25 mg – **1% DV Dec-19 to 2022** ..... 6.50 50 **Hygroton**

47 NORADRENALINE (new listing)
Inj 0.1 mg per ml, 50 ml syringe

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2019 (continued)

47 NICORANDIL (↓ price and addition of HSS)

Tab 10 mg – **1% DV Dec-19 to 2022**	25.57	60	**Ikorel**
Tab 20 mg – **1% DV Dec-19 to 2022**	32.28	60	**Ikorel**

49 SILDENAFIL (amended restriction – affected criteria shown only)

➔ Tab 25 mg – **1% DV Sep-18 to 2021**	0.64	4	**Vedafil**
➔ Tab 50 mg – **1% DV Sep-18 to 2021**	0.64	4	**Vedafil**
➔ Tab 100 mg – **1% DV Sep-18 to 2021**	6.60	12	**Vedafil**

➔ Inj 0.8 mg per ml, 12.5 ml vial

Restricted
Initiation – tablets other conditions
Any of the following:
1 For use in weaning patients from inhaled nitric oxide; or
2 For perioperative use in cardiac surgery patients; or
3 For use in intensive care as an alternative to nitric oxide; **or**
4 For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

DERMATOLOGICALS

53 CETOMACROGOL WITH GLYCEROL (↓ price, addition of HSS and note)

Crm 90% with glycerol 10% – **1% DV Dec-19 to 2022**	1.65	100 g	**healthE**

Note: DV limit applies to the pack sizes of 100 g or less.

GENITO-URINARY SYSTEM

58 MEDROXYPROGESTERONE ACETATE (↑ price and addition of HSS)

Inj 150 mg per ml, 1 ml syringe – **1% DV Dec-19 to 2022**	7.98	1	**Depo-Provera**

INFECTIONS

75 CLARITHROMYCIN (↑ price)

➔ Grans for oral liq 50 mg per ml	192.00	50 ml	Klacid

75 ERYTHROMYCIN (AS LACTOBIONATE) (↓ price and addition of HSS)

Inj 1 g vial – **1% DV Dec-19 to 2022**	10.00	1	**Erythrocin IV**

88 RALTEGRAVIR POTASSIUM (new listing)

➔ Tab 600 mg	1,090.00	60	Isentress HD

NERVOUS SYSTEM

104 KETAMINE (pack size change)

Inj 1 mg per ml, 100 ml bag – **1% DV Feb-20 to 2022**	270.00	10	**Biomed**
Inj 10 mg per ml, 10 ml syringe – **1% DV Feb-20 to 2022**	70.00	5	**Biomed**

Note – Biomed inj 1 mg per ml, 100 ml bag; 1 pack and inj 10 mg per ml, 10 ml syringe; 1 pack to be delisted from 1 February 2020.

Changes to Section H Part II – effective 1 September 2019 (continued)

104 PROPOFOL (amended presentation description)
Inj 10 mg per ml, 20 ml ~~vial~~ **ampoule**
– 10% DV Dec-19 to 2022 ..... 4.35 — 5 — **Fresofol 1% MCT/LCT**

108 SUCROSE (new listing)
Oral liq 25% – **1% DV Feb-20 to 2022** ..... 13.00 — 25 ml — **Biomed**

115 SUMATRIPTAN (↑ price)
Inj 12 mg per ml, 0.5 ml prefilled pen ..... 81.15 — 2 — Clustran

117 AMISULPRIDE (delisting)
Oral liq 100 mg per ml ..... 65.53 — 60 ml — Solian
Note – Solian oral liq 100 mg per ml to be delisted from 1 July 2020.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

129 CARMUSTINE (new listing)
Inj 100 mg vial ..... 1,387.00 — 1 — Bicnu Heritage

136 OXALIPLATIN (brand change)
Inj 5 mg per ml, 20 ml vial – **1% DV Feb-20 to 2021** ..... 46.32 — 1 — **Oxaliplatin Accord**
Note – Oxaliccord inj 5 mg per ml, 20 ml vial to be delisted from 1 February 2020.

142 DEXRAZOXANE (new listing)
➔ Inj 500 mg — *e.g. Cardioxane*

Restricted
Initiation
Medical oncologist, paediatric oncologist, haematologist, paediatric haematologist
All of the following:
1 Patient is to receive treatment with high dose anthracycline given with curative intent; and
2 Based on current treatment plan, patient's cumulative lifetime dose of anthracycline will exceed 250mg/m^2 doxorubicin equivalent or greater; and
3 Dexrazoxane to be administered only whilst on anthracycline treatment; and
4 Either:
4.1 Treatment to be used as a cardioprotectant for a child or young adult; or
4.2 Treatment to be used as a cardioprotectant for secondary malignancy.

145 TACROLIMUS (new listing)
➔ Cap 0.75 mg ..... 99.30 — 100 — Tacrolimus Sandoz

145 TACROLIMUS (↓ price)
➔ Cap 0.5 mg ..... 49.60 — 100 — Tacrolimus Sandoz
➔ Cap 1 mg ..... 84.30 — 100 — Tacrolimus Sandoz
➔ Cap 5 mg ..... 248.20 — 50 — Tacrolimus Sandoz

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2019 (continued)

151 ADALIMUMAB (amended restriction – new criteria shown only)

➔ Inj 20 mg per 0.4 ml syringe	1,599.96	2	Humira
➔ Inj 40 mg per 0.8 ml pen	1,599.96	2	HumiraPen
➔ Inj 40 mg per 0.8 ml syringe	1,599.96	2	Humira

Restricted
Initiation – severe ocular inflammation
Re-assessment required after 4 months
Either
1 Both:
1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and
1.2 Either:
1.2.1 The patient has experienced intolerable side effects from infliximab; or
1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or
2 Both:
2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
2.2 Any of the following:
2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation – severe ocular inflammation
Re-assessment required after 12 months
Both
1 Any of the following:
1.1 The patient has had a good clinical response following 3 initial doses; or
1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.
Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initiation – chronic ocular inflammation
Re-assessment required after 4 months
Either
1 Both:
1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and
1.2 Either:
1.2.1 The patient has experienced intolerable side effects from infliximab; or
1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for chronic ocular inflammation; or
2 Both:
2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and

continued...

Changes to Section H Part II – effective 1 September 2019 (continued)

continued...

2.2 Any of the following:
2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation – chronic ocular inflammation
Re-assessment required after 12 months
Both
1 Any of the following:
1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.
Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

160 INFLIXIMAB (amended restriction criteria – affected criteria shown only)
➔ Inj 100 mg – **10% DV Mar-15 to 29 Feb 2020** ..... 806.00 1 **Remicade**

Initiation – severe ocular inflammation
Re-assessment required after 3 doses
Either
1 Both:
1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
1.2 Either:
1.2.1 The patient has experienced intolerable side effects from adalimumab; or
1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or
2 ~~Either~~ **Both**:
2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
2.2 ~~Either~~ **Any of the following**:
2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
2.2.3 **Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.**

Continuation – severe ocular inflammation
Re-assessment required after 12 months
Any of the following:
1 The patient has had a good clinical response following 3 initial doses; or
2 **Following each 12-month treatment period**, ~~T~~the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

continued...

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2019 (continued)

continued...

3 **Following each 12-month treatment period,** ~~T~~the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – chronic ocular inflammation
Re-assessment required after 3 doses
~~Both~~ **Either**

1 Both:
- **1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and**
- **1.2 Either:**
  - **1.2.1 The patient has experienced intolerable side effects from adalimumab; or**
  - **1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or**

2 ~~Either~~ **Both**:
- **2.**1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- **2.**2 ~~Either~~ **Any of the following**:
  - **2.**2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
  - **2.**2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose**; or**
  - **2.**2.3 **Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.**

Continuation – chronic ocular inflammation
Re-assessment required after 12 months
Any of the following:

1 The patient has had a good clinical response following 3 initial doses; or
2 **Following each 12-month treatment period,** ~~T~~the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
3 **Following each 12-month treatment period,** ~~T~~the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

SENSORY ORGANS

200 CARBACHOL (new listing)
Inj 150 mcg vial

VARIOUS

205 POVIDONE-IODINE (↓ price and addition of HSS)
Soln 10% – **1% DV Nov-19 to 2021** ..... 2.55 100 ml **Riodine**

Changes to Section H Part II – effective 1 August 2019

ALIMENTARY TRACT AND METABOLISM

6 HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE (new listing)
Topical aerosol foam, 1% with pramoxine hydrochloride 1%

7 RANITIDINE (↑ price)
Inj 25 mg per ml, 2 ml ampoule ..... 13.40 5 Zantac

12 LACTULOSE (↑ price and addition of HSS)
Oral liq 10 g per 15 ml – **1% DV Nov-19 to 2022** ..... 3.33 500 ml **Laevolac**

12 SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE (↑ price and addition of HSS)
Enema 90 mg with sodium lauryl sulphoacetate
9 mg per ml, 5 ml – **1% DV Nov-19 to 2022** ..... 29.98 50 **Micolette**

18 FERROUS ~~SULPHATE~~ **SULFATE** (amended chemical name, ↑ price and addition of HSS)
Oral liq 30 mg (6 mg elemental) per ml
– 1% DV Nov-19 to 2022 ..... 12.08 500 ml **Ferodan**

18 IRON POLYMALTOSE (new listing)
Inj 50 mg per ml, 2 ml ampoule ..... 15.22 5 Ferrum H

19 HYALURONIC ACID WITH LIDOCAINE [LIGNOCAINE] (new listing)
Inj 20 mg per ml

21 PYRIDOXINE HYDROCHLORIDE (new listing)
Inj 100 mg per ml, 2 ml vial

31 LYSINE ACETYLSALICYLATE (new listing)
➔ Inj 500 mg *e.g. Aspegic*

Restricted
Initiation
Both:
1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and
2 Administration of oral aspirin would delay the procedure.

BLOOD AND BLOOD FORMING ORGANS

29 DALTEPARIN (delisting)
Inj 2,500 iu in 0.2 ml syringe ..... 19.97 10 Fragmin
Inj 5,000 iu in 0.2 ml syringe ..... 39.94 10 Fragmin
Inj 7,500 iu in 0.75 ml syringe ..... 60.03 10 Fragmin
Inj 10,000 iu in 1 ml syringe ..... 77.55 10 Fragmin
Note – Fragmin inj 2,500 iu in 0.2 ml syringe, 5,000 iu in 0.2 ml syringe, 7,500 iu in 0.75 ml syringe and 10,000 iu in 1 ml syringe to be delisted from 1 April 2020.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 August 2019 (continued)

29 DALTEPARIN (delisting)

Inj 12,500 iu in 0.5 ml syringe	99.96	10	Fragmin
Inj 15,000 iu in 0.6 ml syringe	120.05	10	Fragmin
Inj 18,000 iu in 0.72 ml syringe	158.47	10	Fragmin

Note – Fragmin inj 12,500 iu in 0.5 ml syringe, 15,000 iu in 0.6 ml syringe and 18,000 iu in 0.72 ml syringe to be delisted from 1 January 2020.

30 WARFARIN SODIUM (↑ price)

Tab 1 mg	7.60	100	Marevan
Tab 3 mg	11.80	100	Marevan
Tab 5 mg	13.50	100	Marevan

31 ASPIRIN (↓ price and addition of HSS)

Tab 100 mg – **10% DV Nov-19 to 2022**	10.80	990	**Ethics Aspirin EC**

CARDIOVASCULAR SYSTEM

38 PHENOXYBENZAMINE HYDROCHLORIDE (new listing)
Inj 50 mg per ml, 1 ml ampoule

39 DIGOXIN (↑ price and addition of HSS)

Tab 62.5 mcg – **1% DV Nov-19 to 2022**	7.00	240	**Lanoxin PG**
Tab 250 mcg – **1% DV Nov-19 to 2022**	15.20	240	**Lanoxin**

41 LABETALOL (delisted)
Tab 400 mg
Note – labetalol tab 400 mg delisted 1 August 2019.

43 FUROSEMIDE [FRUSEMIDE] (brand change)

Tab 40 mg – **1% DV Dec-19 to 2022**	7.24	1,000	**Apo-Furosemide**

Note – Diurin 40 tab 40 mg to be delisted from 1 December 2019.

43 FUROSEMIDE [FRUSEMIDE] (new listing)

Oral liq 10 mg per ml – **1% DV Jan-20 to 2022**	11.20	30 ml	**Lasix**
Inj 10 mg per ml, 25 ml ampoule – **1% DV Jan-20 to 2022**	60.65	6	**Lasix**

44 SPIRONOLACTONE (↑ price and addition of HSS)

Oral liq 5 mg per ml – **1% DV Nov-19 to 2022**	30.60	25 ml	**Biomed**

50 ILOPROST (brand change)

Inj 50 mcg in 0.5 ml ampoule – **1% DV Jan-20 to 2022**	305.00	5	**Clinect**

Note – Ilomedin inj 50 mcg in 0.5 ml ampoule to be delisted from 1 January 2020.

DERMATOLOGICALS

54 CLOBETASOL PROPIONATE (↓ price and addition of HSS)

Crm 0.05% – **1% DV Nov-19 to 2022**	2.18	30 g	**Dermol**
Oint 0.05% – **1% DV Nov-19 to 2022**	2.12	30 g	**Dermol**

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 August 2019 (continued)				
55	CLOBETASOL PROPIONATE (↓ price and addition of HSS) Scalp app 0.05% – **1% DV Nov-19 to 2022**	5.69	30 ml	**Dermol**
GENITO-URINARY SYSTEM				
58	INTRA-UTERINE DEVICE (↓ price and addition of HSS) IUD 29.1 mm length × 23.2 mm width – **1% DV Nov-19 to 2022**	18.45	1	**Choice TT380 Short**
	IUD 33.6 mm length × 29.9 mm width – **1% DV Nov-19 to 2022**	18.45	1	**Choice TT380 Standard**
	IUD 35.5 mm length × 19.6 mm width – **1% DV Nov-19 to 2022**	15.50	1	**Choice Load 375**
INFECTIONS				
73	CEFALEXIN (↓ price and addition of HSS) Cap 250 mg – **1% DV Nov-19 to 2022**	3.33	20	**Cephalexin ABM**
73	CEFUROXIME (↑ price and addition of HSS) Tab 250 mg – **1% DV Feb-20 to 2022**	45.93	50	**Zinnat**
73	CEFTRIAXONE (brand change) Inj 500 mg vial – **1% DV Jan-20 to 2022**	0.89	1	**Ceftriaxone-AFT**
	Inj 1 g vial – **1% DV Jan-20 to 2022**	3.99	5	**Ceftriaxone-AFT**
	Note – DEVA inj 500 mg and 1 g vial to be delisted from 1 January 2020.			
73	CEFTRIAXONE (↓ price and addition of HSS) Inj 2 g vial – **1% DV Jan-20 to 2022**	1.98	1	**Ceftriaxone-AFT**
75	ROXITHROMYCIN (↑ price) ➔ Tab dispersible 50 mg	8.29	10	Rulide D
80	ITRACONAZOLE (↑ price and addition of HSS) ➔ Cap 100 mg – **1% DV Nov-19 to 2022**	4.27	15	**Itrazole**
84	PENTAMIDINE ISETHIONATE (↑ price and addition of HSS) ➔ Inj 300 mg vial – **1% DV Nov-19 to 2022**	216.00	5	**Pentacarinat**
MUSCULOSKELETAL SYSTEM				
94	PYRIDOSTIGMINE BROMIDE (↑ price and addition of HSS) Tab 60 mg – **1% DV Nov-19 to 2022**	45.79	100	**Mestinon**

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 August 2019 (continued)

NERVOUS SYSTEM

104 KETAMINE (new listing)
Inj 100 mg per ml, 2 ml vial ..... 155.60 5 Ketamine-Claris

105 BUPIVACAINE HYDROCHLORIDE WITH FENTANYL (↑ price and addition of HSS)
Inj 1.25 mg with fentanyl 2 mcg per ml,
100 ml bag – **1% DV Nov-19 to 2022** ..... 225.00 10 **Bupafen**
Inj 1.25 mg with fentanyl 2 mcg per ml,
200 ml bag – **1% DV Nov-19 to 2022** ..... 235.00 10 **Bupafen**

106 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↑ price and addition of HSS)
Inj 2%, 5 ml ampoule – **1% DV Nov-19 to 2022** ..... 8.25 25 **Lidocaine-Claris**

106 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE (↑ price and addition of HSS)
Inj 1% with adrenaline 1:100,000, 5 ml ampoule
– **1% DV Nov-19 to 2022** ..... 29.00 10 **Xylocaine**

107 PARACETAMOL (↑ price and addition of HSS)
Suppos 25 mg – **1% DV Nov-19 to 2022** ..... 58.50 20 **Biomed**
Suppos 50 mg – **1% DV Nov-19 to 2022** ..... 58.50 20 **Biomed**

108 FENTANYL (↑ price and addition of HSS)
Inj 10 mcg per ml, 100 ml bag – **1% DV Nov-19 to 2022** ..... 220.00 10 **Biomed**

112 ETHOSUXIMIDE (pack size change)
Cap 250 mg ..... 140.88 100 Zarontin
Note – the 200 tab pack (Pharmacode 208876) to be delisted from 1 November 2019.

117 AMISULPRIDE (↑ price and addition of HSS)
Tab 100 mg – **1% DV Nov-19 to 2022** ..... 5.15 30 **Sulprix**
Tab 200 mg – **1% DV Nov-19 to 2022** ..... 14.96 60 **Sulprix**

117 CHLORPROMAZINE HYDROCHLORIDE (new listing)
Tab 10 mg – **1% DV Jan-20 to 2022** ..... 14.83 100 **Largactil**
Tab 25 mg – **1% DV Jan-20 to 2022** ..... 15.62 100 **Largactil**
Tab 100 mg – **1% DV Jan-20 to 2022** ..... 36.73 100 **Largactil**
Inj 25 mg per ml, 2 ml ampoule – **1% DV Jan-20 to 2022** ..... 30.79 10 **Largactil**

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

130 FLUDARABINE PHOSPHATE (↑ price and addition of HSS)
Inj 50 mg vial – **1% DV Nov-19 to 2022** ..... 576.45 5 **Fludarabine Ebewe**

142 CALCIUM FOLINATE (↑ price and addition of HSS)
Inj 10 mg per ml, 10 ml vial – **1% DV Jan-20 to 2022** ..... 9.49 1 **Calcium Folinate Sandoz**
Inj 10 mg per ml, 35 ml vial – **1% DV Nov-19 to 2022** ..... 25.14 1 **Calcium Folinate Sandoz**

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 August 2019 (continued)

142 CALCIUM FOLINATE (delisting)

Inj 10 mg per ml, 10 ml vial	7.33	1	Calcium Folinate Ebewe

Note – Calcium Folinate Ebewe inj 10 mg per ml, 10 ml vial to be delisted from 1 January 2020.

142 MESNA (↑ price and addition of HSS)

Tab 400 mg – **1% DV Nov-19 to 2022**	314.00	50	**Uromitexan**
Tab 600 mg – **1% DV Nov-19 to 2022**	448.50	50	**Uromitexan**
Inj 100 mg per ml, 4 ml ampoule – **1% DV Nov-19 to 2022**	177.45	15	**Uromitexan**
Inj 100 mg per ml, 10 ml ampoule – **1% DV Nov-19 to 2022**	407.40	15	**Uromitexan**

151 ADALIMUMAB (amended restriction criteria – new criteria shown only)

➔ Inj 20 mg per 0.4 ml syringe	1,599.96	2	Humira
➔ Inj 40 mg per 0.8 ml pen	1,599.96	2	HumiraPen
➔ Inj 40 mg per 0.8 ml syringe	1,599.96	2	Humira

Restricted
Initiation – severe Behcet's disease
Any relevant practitioner
Re-assessment required after 3 months
All of the following:
1 The patient has severe Behcet's disease that is significantly impacting the patient's quality of life (see Notes); and
2 Either:
  2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or
  2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and
3 The patient is experiencing significant loss of quality of life; and
4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Notes: Behcet's disease diagnosed according to the International Study Group for Behcet's disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al, J Rheumatol. 2004;31:931-7

Continuation – severe Behcet's disease
Any relevant practitioner
Re-assessment required after 6 months
Both:
1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 August 2019 (continued)

159 BEVACIZUMAB (amended restriction criteria)

➔ Inj 25 mg per ml, 4 ml vial

➔ Inj 25 mg per ml, 16 ml vial

Restricted

Initiation – Recurrent Respiratory Papillomatosis
Otolaryngologist
Re-assessment required after 12 months
All of the following:
1 Maximum of 6 doses; and
2 The patient has recurrent respiratory papillomatosis; and
3 The treatment is for intra-lesional administration

Continuation – Recurrent Respiratory Papillomatosis
Otolaryngologist
Re-assessment required after 12 months
All of the following:
1 Maximum of 6 doses; and
2 The treatment is for intra-lesional administration; and
3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

Initiation – **ocular conditions**
Either:
1 Ocular neovascularisation; or
2 Exudative ocular angiopathy.

169 RITUXIMAB (amended restriction criteria – new criteria shown only)

➔ Inj 10 mg per ml, 10 ml vial	1,075.50	2	Mabthera
➔ Inj 10 mg per ml, 50 ml vial	2,688.30	1	Mabthera

Restricted

Initiation – Neuromyelitis Optica Spectrum Disorde (NMOSD)
Relevant specialist or medical practitioner on the recommendation of a relevant specialist.
Re-assessment required after 6 months
Both:
1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m^2 administered weekly for four weeks; and
2 Either:
  2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
  2.2 All of the following:
    2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
    2.2.2 The patient is receiving treatment with mycophenolate; and
    2.2.3 The patients is receiving treatment with corticosteroids.

Continuation – Neuromyelitis Optica Spectrum Disorder (NMOSD)
Relevant specialist or medical practitioner on the recommendation of a relevant specialist.
Re-assessment required after 2 years
All of the following:
1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m^2 administered weekly for four weeks; and
2 The patients has responded to the most recent course of rituximab; and
3 The patient has not received rituximab in the previous 6 months.

continued...

Changes to Section H Part II – effective 1 August 2019 (continued)

continued...

Initiation – Severe Refractory Myasthenia Gravis
Neurologist or medical practitioner on the recommendation of a neurologist.
Re-assessment required after 2 years
Both:
1 One of the following dose regimens is to be used: 375 mg/m^2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
2 Either:
  2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
  2.2 Both:
    2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
    2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Continuation – Severe Refractory Myasthenia Gravis
Neurologist or medical practitioner on the recommendation of a neurologist.
Re-assessment required after 2 years
All of the following:
1 One of the following dose regimens is to be used: 375 mg/m^2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
2 An initial response lasting at least 12 months was demonstrated; and
3 Either:
  3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
  3.2 Both
    3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
    3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

186	AZATHIOPRINE (brand change)			
	Tab 25 mg – **1% DV Jan-20 to 2022**	7.35	60	**Azamun**
	Tab 50 mg – **1% DV Jan-20 to 2022**	7.60	100	**Azamun**
	Note – Imuran tab 25 mg and 50 mg to be delisted from 1 January 2020.			
186	AZATHIOPRINE (↑ price and addition of HSS)			
	Inj 50 mg vial – **1% DV Nov-19 to 2022**	199.00	1	**Imuran**

RESPIRATORY SYSTEM AND ALLERGIES

189	CETIRIZINE HYDROCHLORIDE (↑ price and addition of HSS)			
	Tab 10 mg – **1% DV Nov-19 to 2022**	1.12	100	**Zista**
189	IPRATROPIUM BROMIDE (↑ price and addition of HSS)			
	Nebuliser soln 250 mcg per ml, 2 ml ampoule – **1% DV Jan-20 to 2022**	11.73	20	**Univent**
193	MONTELUKAST (brand change)			
	Tab 4 mg – **1% DV Jan-20 to 2022**	4.25	28	**Montelukast Mylan**
	Tab 10 mg – **1% DV Jan-20 to 2022**	3.95	28	**Montelukast Mylan**
	Note – Apo-Montelukast tab 4 mg and 10 mg to be delisted from 1 January 2020.			

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 August 2019 (continued)

194 CAFFEINE CITRATE (↑ price and addition of HSS)
Oral liq 20 mg per ml (caffeine 10 mg per ml)
– **1% DV Nov-19 to 2022** ..... 15.10 25 ml **Biomed**
Inj 20 mg per ml (caffeine 10 mg per ml),
2.5 ml ampoule – **1% DV Nov-19 to 2022** ..... 63.25 5 **Biomed**

194 THEOPHYLLINE (new listing)
Tab long-acting 250 mg – **1% DV Jan-20 to 2022** ..... 23.02 100 **Nuelin-SR**
Oral liq 80 mg per 15 ml – **1% DV Jan-20 to 2022** ..... 16.60 500 ml **Nuelin**

194 SODIUM CHLORIDE (↑ price and addition of HSS)
Nebuliser soln 7%, 90 ml bottle – **1% DV Nov-19 to 2022** ..... 24.50 90 ml **Biomed**

SENSORY ORGANS

196 CHLORAMPHENICOL (addition of HSS)
Eye drops 0.5% – **1% DV Nov-19 to 2022** ..... 1.54 10 ml **Chlorafast**

198 SODIUM CROMOGLICATE (new listing)
Eye drops 2% – **1% DV Jan-20 to 2022** ..... 1.79 5 ml **Rexacrom**

200 TIMOLOL (delisting)
Eye drops 0.25%, gel forming ..... 3.30 2.5 ml Timoptol XE
Note – Timoptol XE eye drops 0.25%, gel forming to be delisted from 1 January 2020.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

211 COAL TAR (↑ price and addition of HSS)
Soln BP – **1% DV Nov-19 to 2022** ..... 36.25 200 ml **Midwest**

212 MAGNESIUM HYDROXIDE (new listing)
Suspension

212 SODIUM BICARBONATE (new listing)
Powder BP – **1% DV Jan-20 to 2022** ..... 10.05 500 g **Midwest**

213 SYRUP (pack size change)
Liq (pharmaceutical grade) – **1% DV Jan-20 to 2022** ..... 14.95 500 ml **Midwest**
Note – Midwest liq (pharmaceutical grade), 2,000 ml bottle pack to be delisted from 1 January 2020.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 August 2019 (continued)

VACCINES

234 HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] (amended restriction criteria – new criteria shown only)

➔ Inj 270 mcg in 0.5 ml syringe – **0% DV Jun-17 to 2020** ..... 0.00 10 **Gardasil 9**

Restricted
Initiation – (Recurrent Respiratory Papillomatosis)
All of the following:
1 Either:
  1.1 Maximum of two doses for children aged 14 years and under; or
  1.2 Maximum of three doses for people aged 15 years and over.
2 The patient has recurrent respiratory papillomatosis; and
3 The patient has not previously had an HPV vaccine.

Index

Pharmaceuticals and brands

Index
Pharmaceuticals and brands

New Zealand
Permit No. 478

Permit

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1172-3694 (Print)
ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand